{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:42:53Z","timestamp":1768315373659,"version":"3.49.0"},"reference-count":32,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The efficacy of vortioxetine has been proven in many studies, but data concerning discontinuation symptoms (DS) after vortioxetine withdrawal is scarce. The aim of our study is to systematically evaluate the prevalence, determinants, and clinical features of vortioxetine DS in a retrospective chart review. Data were obtained from medical records of 263 adult patients with depressive disorders who discontinued former vortioxetine treatment. DS were observed in eight (3%) patients after 71\u2013375 days (median 272) of treatment. DS emerged after median three days following vortioxetine withdrawal and lasted for median seven days. The clinical presentation of DS involved: emotional lability (100% of patients), irritability (75%), sudden worsening of mood (75%), nervousness (37.5%), and agitation (37.5%). Median DESS score was four (range of four to six). DS were significantly more prevalent after accidental vs. planned discontinuation (adjusted p = 0.011) and were less frequent after switching to a different antidepressant vs. ceasing pharmacotherapy (adjusted p = 0.0165). DS appeared more often if patients discontinued therapy without medical consultation (adjusted p = 0.033). The occurrence of DS was not associated with the dose and way of drug discontinuation (sudden vs. gradual). In sum, our results show that clinicians should be aware that vortioxetine withdrawal is associated with the possibility of DS.<\/jats:p>","DOI":"10.3390\/ph14050451","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T04:05:32Z","timestamp":1620705932000},"page":"451","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Withdrawal Symptoms Following Discontinuation of Vortioxetine\u2014Retrospective Chart Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3109-1895","authenticated-orcid":false,"given":"Marcin","family":"Siwek","sequence":"first","affiliation":[{"name":"Department of Affective Disorders, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-9980","authenticated-orcid":false,"given":"Adrian Andrzej","family":"Chrobak","sequence":"additional","affiliation":[{"name":"Department of Adult Psychiatry, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Gorostowicz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3291-9663","authenticated-orcid":false,"given":"Anna Julia","family":"Krupa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Dudek","sequence":"additional","affiliation":[{"name":"Department of Adult Psychiatry, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"ref_1","unstructured":"Grohol, J. (2021, April 18). Top 25 Psychiatric Medication Prescriptions for 2013. Available online: https:\/\/psychcentral.com\/lib\/top-25-psychiatric-medication-prescriptions-for-2013\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/070674375900400111","article-title":"Clinical experience with imipramine (G22355) in the treatment of depression","volume":"4","author":"Mann","year":"1959","journal-title":"Can. Psychiatr. Assoc. J."},{"key":"ref_3","first-page":"76","article-title":"Switching and stopping antidepressants","volume":"39","author":"Keks","year":"2016","journal-title":"Aust. Prescr."},{"key":"ref_4","first-page":"545","article-title":"Zesp\u00f3\u0142 objaw\u00f3w odstawiennych po lekach antydepresyjnych w badaniach naukowych-Implikacje dla lekarzy i pacjent\u00f3w","volume":"43","author":"Heitzman","year":"2009","journal-title":"Psychiatr. Pol."},{"key":"ref_5","first-page":"449","article-title":"Antidepressant discontinuation syndrome","volume":"74","author":"Warner","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.18773\/austprescr.2001.008","article-title":"Stopping antidepressants","volume":"24","author":"Schweitzer","year":"2001","journal-title":"Aust. Prescr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1192\/apt.bp.105.001966","article-title":"Recognising and managing antidepressant discontinuation symptoms","volume":"13","author":"Haddad","year":"2007","journal-title":"Adv. Psychiatr. Treat."},{"key":"ref_8","unstructured":"Ivd, W., Ashby, D., Brook, R., Mga, C., Chick, J., Drummond, C., Ebmeier, K.P., Gunnell, D., Hawking, H., and Mukaetova-Ladinska, E. (2005). Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants, MHRA."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000447034","article-title":"The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother. Psychosom."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000370338","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review","volume":"84","author":"Fava","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"ref_11","first-page":"22","article-title":"Venlafaxine and serious withdrawal symptoms: Warning to drivers","volume":"7","author":"Campagne","year":"2005","journal-title":"Med. Gen. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jad.2005.09.003","article-title":"Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder","volume":"89","author":"Perahia","year":"2005","journal-title":"J. Affect. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/026988110201600314","article-title":"Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms","volume":"16","author":"Curtin","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"ref_14","unstructured":"(2021, April 11). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020415s030lbl.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4103\/0976-500X.171878","article-title":"Mirtazapine withdrawal-induced mania","volume":"6","author":"Verma","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_16","first-page":"143","article-title":"Mirtazapine-Associated Withdrawal Symptoms: A Case Report","volume":"3","author":"Berigan","year":"2001","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1440-1819.1989.tb02564.x","article-title":"Panic Anxiety after Abrupt Discontinuation of Mianserin","volume":"43","author":"Kuniyoshi","year":"1989","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_18","first-page":"603","article-title":"Efficacy and tolerability of agomelatine in the treatment of depression","volume":"8","year":"2014","journal-title":"Patient Prefer. Adherence"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1176\/ajp.148.9.1263a","article-title":"Extrapyramidal symptoms upon discontinuation of fluoxetine","volume":"148","author":"Stoukides","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/0269881109359094","article-title":"Antidepressant discontinuation manic states: A critical review of the literature and suggested diagnostic criteria","volume":"25","author":"Narayan","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clineuro.2007.08.016","article-title":"Delirium following abrupt discontinuation of fluoxetine","volume":"110","author":"Blum","year":"2008","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_22","first-page":"1236","article-title":"Delirium bij afbouw van venlafaxine","volume":"146","author":"Vergouwen","year":"2002","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.5664\/jcsm.2848","article-title":"Status cataplecticus precipitated by abrupt withdrawal of venlafaxine","volume":"9","author":"Wang","year":"2013","journal-title":"J. Clin. Sleep Med."},{"key":"ref_24","first-page":"117","article-title":"Venlafaxine withdrawal syndrome","volume":"23","author":"Rakun","year":"2011","journal-title":"Psychiatr. Danub."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/026988110101500210","article-title":"Antidepressant discontinuation (withdrawal) symptoms presenting as \u201cstroke\u201d","volume":"15","author":"Haddad","year":"2001","journal-title":"J. Psychopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.14m09335","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder","volume":"76","author":"Jacobsen","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_28","first-page":"715","article-title":"Discontinuation-emergent signs and symptoms inventory-Polish translation of the discontinuation signs and symptoms checklist","volume":"47","author":"Landowski","year":"2013","journal-title":"Psychiatr. Pol."},{"key":"ref_29","unstructured":"Rosenthal, R. (2011). Meta-Analytic Procedures for Social Research, SAGE Publications, Inc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.14r09164","article-title":"The US Food and Drug Administration\u2019s perspective on the new antidepressant vortioxetine","volume":"76","author":"Zhang","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","article-title":"Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial","volume":"44","author":"Rosenbaum","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.pharep.2017.01.030","article-title":"Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant","volume":"69","author":"Misztak","year":"2017","journal-title":"Pharmacol. Rep."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/5\/451\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:59:01Z","timestamp":1760162341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/5\/451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ph14050451"],"URL":"https:\/\/doi.org\/10.3390\/ph14050451","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]}}}